About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Ptpn2
protein tyrosine phosphatase, non-receptor type 2
MGI:97806
96 phenotypes from 5 alleles in 7 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Ptpn2tm1.1Kry/Ptpn2tm1.1Kry
Tg(Col1a1-cre)1Kry/0
involves: 129 * C57BL/6J * FVB 		abnormal osteoclast differentiation J:183709
abnormal osteoclast physiology J:183709
normal homeostasis/metabolism phenotype J:183709
increased bone resorption J:183709
increased carbon dioxide production J:183709
increased circulating osteocalcin level J:183709
increased energy expenditure J:183709
increased insulin sensitivity J:183709
increased oxygen consumption J:183709
normal skeleton phenotype J:183709
Ptpn2tm1.1Ttig/Ptpn2tm1.1Ttig
Tg(Nes-cre)1Kln/0
involves: C57BL/6 * C57BL/6J * SJL 		abnormal eating behavior J:179621
abnormal glucose homeostasis J:179621
decreased body length J:179621
decreased body weight J:179621
decreased bone marrow cell number J:179621
decreased bone mineral content J:179621
decreased bone mineral density J:179621
decreased bone trabecula number J:179621
decreased circulating glucose level J:179621
decreased circulating growth hormone level J:179621
decreased circulating insulin level J:179621
decreased circulating insulin-like growth factor I level J:179621
decreased circulating leptin level J:179621
decreased locomotor activity J:179621
decreased susceptibility to diet-induced obesity J:179621
decreased trabecular bone volume J:179621
increased adiponectin level J:179621
increased energy expenditure J:179621
increased insulin sensitivity J:179621
increased oxygen consumption J:179621
increased response to leptin J:179621
increased total body fat amount J:179621
Ptpn2tm1a(EUCOMM)Wtsi/Ptpn2+
C57BL/6N-Ptpn2tm1a(EUCOMM)Wtsi/Wtsi 		increased hemoglobin content J:175295
increased mean corpuscular hemoglobin J:175295
Ptpn2tm1Mtr/Ptpn2tm1Mtr
B6.129S4(C)-Ptpn2tm1Mtr 		abnormal bone marrow cell number J:186843
abnormal lymph node morphology J:186843
decreased B cell number J:186843
decreased B-1 B cell number J:186843
decreased body size J:186843
decreased bone marrow cell number J:186843
decreased bone mineral content J:186843
decreased CD4-positive, alpha-beta T cell number J:186843
decreased double-positive T cell number J:186843
decreased erythrocyte cell number J:186843
decreased erythroid progenitor cell number J:186843
decreased follicular B cell number J:186843
decreased immature B cell number J:186843
decreased lean body mass J:186843
decreased marginal zone B cell number J:186843
decreased mature B cell number J:186843
decreased single-positive T cell number J:186843
decreased T cell number J:186843
decreased thymocyte number J:186843
decreased total body fat amount J:186843
normal hematopoietic system phenotype J:186843
increased bone mineral density J:186843
premature death J:186843
normal skeleton phenotype J:186843
thymus atrophy J:186843
Ptpn2tm1Mtr/Ptpn2tm1Mtr
C.129S4-Ptpn2tm1Mtr 		abnormal bone marrow cell number J:186843
abnormal bone structure J:186843
abnormal bone trabecula morphology J:186843
abnormal long bone epiphyseal ossification zone morphology J:186843
abnormal long bone morphology J:186843
abnormal lymph node morphology J:186843
abnormal negative T cell selection J:186843
abnormal ossification involved in bone maturation J:186843
abnormal pilomotor reflex J:186843
abnormal positive T cell selection J:186843
abnormal skeleton morphology J:186843
abnormal T cell differentiation J:186843
abnormal T cell subpopulation ratio J:186843
decreased B cell number J:186843
decreased B-1 B cell number J:186843
decreased body size J:186843
decreased bone marrow cell number J:186843
decreased bone mineral content J:186843
decreased CD4-positive, alpha-beta T cell number J:186843
decreased diameter of femur J:186843
decreased double-positive T cell number J:186843
decreased erythrocyte cell number J:186843
decreased erythroid progenitor cell number J:186843
decreased follicular B cell number J:186843
decreased immature B cell number J:186843
decreased lean body mass J:186843
decreased locomotor activity J:186843
decreased marginal zone B cell number J:186843
decreased mature B cell number J:186843
decreased single-positive T cell number J:186843
decreased T cell number J:186843
decreased thymocyte number J:186843
decreased total body fat amount J:186843
diarrhea J:186843
enlarged spleen J:186843
hunched posture J:186843
increased bone mineral density J:186843
increased bone trabecula number J:186843
increased splenocyte number J:186843
increased trabecular bone volume J:186843
postnatal lethality, incomplete penetrance J:186843
premature death J:186843
short femur J:186843
thymus atrophy J:186843
Ptpn2tm1Mtr/Ptpn2tm1Mtr
involves: 129S4/SvJae * BALB/c 		abnormal B cell number J:42595
abnormal bone marrow cell morphology/development J:42595
abnormal erythropoiesis J:42595
abnormal inflammatory response J:90541
abnormal spleen morphology J:42595
abnormal thymus involution J:42595
anemia J:42595
decreased B cell number J:42595
decreased double-positive T cell number J:42595
decreased hematocrit J:42595
decreased locomotor activity J:42595
diarrhea J:42595
enlarged lymph nodes J:42595
enlarged spleen J:42595
hunched posture J:42595
increased B cell number J:42595
increased inflammatory response J:90541
increased interferon-gamma secretion J:90541
increased interleukin-12 secretion J:90541
increased macrophage cell number J:42595
increased mature B cell number J:42595
increased pre-B cell number J:42595
increased spleen red pulp amount J:42595
increased tumor necrosis factor secretion J:90541
lymph node hyperplasia J:42595
narrow eye opening J:42595
postnatal growth retardation J:42595
premature death J:42595
spleen hyperplasia J:42595
Ptpn2tm2.1Ttig/Ptpn2tm2.1Ttig
B6.Cg-Ptpn2tm2.1Ttig 		abnormal bone marrow cell number J:186843
abnormal negative T cell selection J:186843
abnormal positive T cell selection J:186843
abnormal skeleton morphology J:186843
abnormal T cell differentiation J:186843
abnormal T cell subpopulation ratio J:186843
decreased B cell number J:186843
decreased B-1 B cell number J:186843
decreased body size J:186843
decreased bone marrow cell number J:186843
decreased bone mineral content J:186843
decreased CD4-positive, alpha-beta T cell number J:186843
decreased double-positive T cell number J:186843
decreased erythrocyte cell number J:186843
decreased erythroid progenitor cell number J:186843
decreased follicular B cell number J:186843
decreased immature B cell number J:186843
decreased lean body mass J:186843
decreased long bone epiphyseal plate size J:186843
decreased marginal zone B cell number J:186843
decreased mature B cell number J:186843
decreased single-positive T cell number J:186843
decreased thymocyte number J:186843
decreased total body fat amount J:186843
enlarged lymph nodes J:186843
normal hematopoietic system phenotype J:186843
increased bone mineral density J:186843
premature death J:186843
normal skeleton phenotype J:186843
thymus atrophy J:186843
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/10/2024
MGI 6.24 		The Jackson Laboratory